Summary
For Year 2026-27, Senores Pharmaceuticals reports the following shareholding: Total Promoters at 45.82%, Mutual Fund at 5.07%, Insurance at 2.96%, Foreign Institutional Investors at 3.64%, Domestic Institutional Investors at 1.58%, and Retail at 40.93%. This breakdown provides a quick snapshot of ownership distribution for Senores Pharmaceuticals in 2026-27.
Senores Pharmaceuticals FAQs
As of 04-2026, the promoter shareholding in Senores Pharmaceuticals stands at 45.82% of the company's total shares. Promoter shareholding represents the ownership stake held by the company's founding members, management, or controlling entities, having a significant influence on the company's strategic direction and operations.
The FII and DII shareholding of Senores Pharmaceuticals is 3.64% and 1.58% respectively.
The retail shareholding of the Senores Pharmaceuticals is 40.93%.
Changes in shareholding patterns of Senores Pharmaceuticals can result from stock market transactions, issuance of new shares, buybacks, mergers, acquisitions, or changes in promoter holdings.
Shareholding patterns of Senores Pharmaceuticals are updated quarterly as mandated by regulatory authorities and may also be disclosed during significant corporate events.
The latest shareholding pattern is available on stock exchanges (e.g., NSE, BSE) and the company's official website under investor relations.
Senores Pharmaceuticals Associated Pages
